comparemela.com

Latest Breaking News On - Spero therapeutics company profile get rating - Page 1 : comparemela.com

Spero Therapeutics, Inc. (NASDAQ:SPRO) Expected to Post Quarterly Sales of $2.65 Million

Brokerages expect Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Rating) to report sales of $2.65 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Spero Therapeutics’ earnings. The lowest sales estimate is $2.30 million and the highest is $3.00 million. Spero Therapeutics posted sales of $5.15 million during the […]

United-states
Berenberg-bank
Goldman-sachs-group-inc
Zacks-investment-research
Spero-therapeutics-company-profile-get-rating
Blackrock-inc
Nasdaq
Marshall-wace
Wells-fargo-company
Cantor-fitzgerald
Spero-therapeutics-inc

Spero Therapeutics (SPRO) Scheduled to Post Earnings on Thursday

Spero Therapeutics (NASDAQ:SPRO – Get Rating) will post its quarterly earnings results after the market closes on Thursday, March 31st. Analysts expect Spero Therapeutics to post earnings of ($0.81) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link. Shares of Spero Therapeutics stock […]

Ankit-mahadevia
Wells-fargo-company
Zacks-investment-research
Spero-therapeutics-company-profile-get-rating
Spero-therapeutics-inc
Aquilo-capital-management-llc
Citigroup-inc
Barclays-plc
Spero-therapeutics
Get-rating
Investment-research
Aquilo-capital-management

vimarsana © 2020. All Rights Reserved.